SPY423.11+2.25 0.53%
DIA339.45+0.67 0.20%
IXIC14,253.27+111.79 0.79%

Piper Sandler Downgrades Halozyme Therapeutics to Neutral, Lowers Price Target to $48

Piper Sandler analyst Joseph Catanzaro downgrades Halozyme Therapeutics (NASDAQ:HALO) from Overweight to Neutral and lowers the price target from $50 to $48.

05/11/2021 07:30
Piper Sandler analyst Joseph Catanzaro downgrades Halozyme Therapeutics (NASDAQ:HALO) from Overweight to Neutral and lowers the price target from $50 to $48.